Zhengye Biotechnology (NASDAQ:ZYBT) Shares Down 2% – Time to Sell?

Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) shares fell 2% during trading on Wednesday . The stock traded as low as $0.9572 and last traded at $1.00. 11,188 shares changed hands during trading, a decline of 22% from the average session volume of 14,273 shares. The stock had previously closed at $1.02.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zhengye Biotechnology in a research note on Friday, January 9th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Zhengye Biotechnology has a consensus rating of “Sell”.

Zhengye Biotechnology Price Performance

The firm has a 50 day moving average price of $1.59 and a 200-day moving average price of $4.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.10 and a current ratio of 1.49.

Institutional Trading of Zhengye Biotechnology

A number of hedge funds have recently bought and sold shares of the company. Citadel Advisors LLC purchased a new position in shares of Zhengye Biotechnology during the 3rd quarter worth about $31,000. Millennium Management LLC purchased a new stake in shares of Zhengye Biotechnology during the third quarter valued at approximately $38,000. WINTON GROUP Ltd acquired a new stake in Zhengye Biotechnology during the 3rd quarter valued at approximately $56,000. Geode Capital Management LLC acquired a new stake in Zhengye Biotechnology in the second quarter valued at $174,000. Finally, Invesco Ltd. bought a new position in shares of Zhengye Biotechnology during the second quarter worth about $220,000.

About Zhengye Biotechnology

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.